Israeli biotech receives $30M: Lutris Pharma reported the funding should help it take a look at a topical gel that aims to cut back EGFRi-induced rashes attributable to selected most cancers medication. In my own tinkering with LLMs to receive them to act scientific, it seems imperative that you